The $33M Baker Bros. purchase is a powerful bullish signal that likely overrides the bearish overhang from the $150M offering. Traders should watch for follow-on buying by other insiders and monitor upcoming TUDRIQEV launch metrics.
Drug in focus
REPL drug pipeline →TUDRIQEV
● Neutral Named in this insider cluster- Impact
- Phase
- Approved (Accelerated Approval)
- Time to market
- Already approved and commercially available in the U.S. since October 2026.
- Next catalyst
- None dated
What to watchTUDRIQEV is now a commercial-stage asset, so the focus shifts from regulatory binary to revenue execution. Watch the next quarterly earnings (likely late January 2027) for early sales figures, formulary adoption metrics, and the permanent J-code expected by April 2027. The confirmatory Phase 3 trial data timeline is the next major binary but has no announced readout date yet.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 13 $15.19entry
- T+1 · 3mo ago −1.45%α −1.25% · $14.97
- T+5 · 3mo ago −7.50%α −5.54% · $14.05
- T+20 · 2mo ago −14.94%α −13.20% · $12.92
- T+60 · 11d ago +39.27%α +44.51% · $21.16
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
A cluster of insider selling by the CMO, CFO, and CAO totaling ~$396K on August 10, 2026, occurred just one day after a $150M dilutive offering closed. However, this selling is dwarfed by a massive $33M open-market purchase by director Baker Bros. Advisors on August 11, 2026, signaling strong insider conviction post-dilution. The net insider direction is strongly bullish when weighted by dollar value, as the Baker Bros. purchase represents ~3% of market cap and is a powerful counter-signal to the routine post-offering sales by executives.
Key Financial Metrics
Key Facts
- Baker Bros. Advisors LP (Director) purchased 2,736,340 shares total for ~$33.0M on August 11, 2026, at $12.06/share.
- Three C-suite executives (CMO, CFO, CAO) sold a combined 30,527 shares for ~$396K on August 10, 2026, at $12.97/share.
- The $33M purchase by Baker Bros. represents ~3% of REPL's $1.1B market cap, a highly material insider buy cluster.
- The insider buying occurred one day after the close of a $150M dilutive public offering, suggesting the buyer sees post-dilution value.
- The C-suite sales are small in absolute terms (~$396K total) and likely routine post-offering liquidity or tax-related transactions.
Financial Impact
Baker Bros. purchased ~$33M of REPL stock at $12.06/share, representing ~3% of market cap. C-suite sales totaled ~$396K, a trivial 0.04% of market cap.
Risk Factors
- The $150M dilutive offering closed just before the insider buying, creating ~13% dilution that could pressure the stock near-term.
- REPL has never generated product revenue and faces confirmatory trial requirements for TUDRIQEV's accelerated approval.
- The C-suite selling, while small, occurred at a slightly higher price ($12.97) than the Baker Bros. purchase ($12.06), which could indicate a lack of alignment among management.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-REPL-1786568741135 |
Track record
32 reports on REPL
8 of 12 bullish or bearish reports moved the stock their way by T+60. Best: +188.35% at T+20 after the Jul 30, 2026 report. 12 of 13 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $21.90 Now $21.41 −2.24% settles Feb 12
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $21.78 Now $21.41 −1.70% settles Feb 9
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $23.28 Now $21.41 −8.03% settles Feb 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $23.28 Now $21.41 −8.03% settles Feb 8
- Nov 9, 20267d ago SC 13G/A Neutral 2/10 Entry $22.26 Now $21.41 −3.82% settles Feb 5
- Nov 6, 202610d ago 10-Q/A Neutral 3/10 Entry $22.26 Now $21.41 −3.82% settles Feb 5
- Nov 4, 202612d ago Institutional Cluster Bearish 4/10 Entry $20.69 Now $21.41 −3.48% settles Feb 2
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $20.69 Now $21.41 +3.48% settles Feb 2
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $20.65 Now $21.41 +3.68% settles Feb 1
- Oct 30, 202617d ago 144 Neutral 2/10 Entry $19.49 Now $21.41 +9.85% settles Jan 29
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers